Abstract This study's aim was to define the clinical manifestations and long-term outcome of pediatric patients living at altitude with isolated pulmonary artery (PA) of ductal origin (IPADO). This was a retrospective cohort study of 17 consecutive cases of IPADO at a single center. All patients lived at modest altitude (median 2050 m [range 1700 m to 3050 m]). Fifteen children (88%) were symptomatic at presentation. High-altitude pulmonary edema was present in 2 patients (12%) at diagnosis, and only 1 patient had episodes of hemoptysis during follow-up. Fourteen patients (82%) demonstrated evidence of pulmonary arterial hypertension (PAH). Among 14 patients with PAH, 11 patients had surgical interventions. PAH resolved in 5 of 11 patients (45%) undergoing surgical rehabilitation. One patient died during follow-up, and 7 patients are receiving oral vasodilator therapies due to residual PAH; 14 patients remained asymptomatic. Our study showed that early intervention in patients with IPADO at modest altitude can potentially rehabilitate the isolated PA and reverse PAH. Whether surgery is indicated for patients with this disorder in the absence of PAH is unknown.
Introduction
Congenital isolated unilateral absence of a pulmonary artery (PA) is a rare entity, with an estimated prevalence of 1/200,000 [4] . The term unilateral ''absence of a pulmonary artery'' is a misnomer, and in most cases pulmonary venous wedge angiography has identified a hidden hypoplastic and disconnected PA at the lung hilum with normal intrapulmonary distribution [6, 7, 22] . The term ''isolated PA of ductal origin'' (IPADO) is more appropriate as the native 6th arch vessel is not absent [17, 27] . Review of published reports identified [ 160 cases of IPADO [10, 13, 21, 26, 29, 32] . Initially, patients with IPADO can remain asymptomatic for a long period, thus the diagnosis may not be made until adulthood [4] . Over time, however, most of these patients develop severe symptomatology including pulmonary arterial hypertension (PAH), hemoptysis, recurrent pulmonary infections, exercise intolerance, unilateral HAPE, and right heart failure (HF) [4, 5, 12, 14, 16, 21, 26, 28, 29] . Some patients with IPADO are unmasked by PAH associated with altitude exposure and hypoxic pulmonary vasoconstriction [8, 19, 20] . At modest altitude (\ 2500 m), minor impairment exists in arterial oxygen transport (arterial oxygen saturation at least 90%) [18] . Preexisting PAH may deteriorate at altitudes [ 2000 m, particularly during exercise [1] . Patients with IPADO and an underdeveloped pulmonary vascular bed are at increased risk to develop exaggerated PAH and HAPE at lower altitudes [9, [23] [24] [25] .
Limited data have been published in the literature except for isolated rare case reports on long-term outcomes of patients with IPADO living at altitude. Consequently, this present retrospective cohort study was undertaken to define the clinical manifestations and long-term outcome of 17 pediatric patients at a single center living at altitude with IPADO.
Methods
In a retrospective cohort study design, we identified 17 consecutive cases presenting with IPADO from 1975 to 2011 from the medical record database at Children's Hospital Colorado. Patients with associated congenital cardiac defects-such as tetralogy of Fallot, pulmonary stenosis, truncus arteriosus, anomalous origin of a PA from the ascending aorta, pulmonary atresia, coarctation of aorta, transposition of great arteries, or ventricular septal defect requiring surgical repair, were excluded. However, IPADO patients associated with a hemodynamically insignificant small intra-cardiac defect and patent ductus arteriosus (PDA)-were included in the study. We reviewed the case records and extracted the clinical data, including altitude of residence; sex; age at diagnosis; symptoms; echocardiographic and hemodynamic data; surgical and transcatheter intervention data, such as age at time of surgery; frequency of surgeries; surgical method to connect IPADO; interval and method of transcatheter intervention after surgical procedure; and subsequent PA development. To confirm IPADO, cardiac catheterization and pulmonary vein angiography was performed in all cases in combination with computed tomography, and/or magnetic resonance imaging angiography. The clinical outcomes included death and World Health Organization (WHO) functional class status at follow-up. PAH was defined by a mean PA pressure (mPAP) [ 25 mm Hg as measured by right heart catheterization. This study protocol was approved by the Institutional Review Board of the University of Colorado, which waived patient consent because of the retrospective data analysis. All results are reported as median and range or mean and SD as appropriate.
Results
Clinical characteristics are listed Table 1 . Age at diagnosis ranged from 1 month to 13 years (median 3 years) with a median follow-up period of 10 years (range 1 to 46). Thirteen patients were male, and 4 were female. No patients had a familial history of the disorder. One patient (patient no. 8) had a small muscular ventricular septal defect, and 6 patients had a PDA (contralateral = 2 patients; ipsilateral = 4 patients). Extracardiac anomalies were associated with chromosome 22q11.2 deletion syndrome in 1 patient (patient no. 6). The IPADO was of the 
Clinical Symptoms and PAH
Median age at onset was 3 years (ranged birth to 13 years). Only 2 patients (patients no. 9 and 12) were asymptomatic and were investigated because of a heart murmur or abnormal chest X-ray (CXR), whereas the remaining 15 patients (88%) were symptomatic due to a cyanotic spell (n = 7 [41%]), dyspnea (n = 5), prolonged cough (n = 2), and fatigue (n = 1) as the initial symptom. HAPE was present in 2 patients (12%) at diagnosis, and 2 patients had recurrent infection before diagnosis. Only 1 patient (patient no. 5), who had not had surgery, had hemoptysis at 11 years of age. He was diagnosed at 4 months of age and moved from high altitude (2500 m, Colorado) to a lower altitude (1100 m, Oregon). The patient underwent coil embolization of three large aortopulmonary collateral vessels and then had an episode of hemoptysis while at altitude 6 weeks after embolization (2006 [15 years old]).
Fourteen patients (82%) demonstrated evidence of PAH before surgery with a median mPAP of 39 mm Hg (range 25 to 58) by cardiac catheterization, and 3 of 14 patients with PAH had congestive HF. The remaining 3 patients showed no evidence of PAH at initial catheterization (mPAP 17 to 20 mm Hg). The median age at onset of symptoms in patients with PAH was 1 year (ranged birth to 9 years), which was younger than those in patients without PAH (median 6 [range 4 to 13]).
Treatments
All treatment strategies and outcome data are listed in detail in Table 2 . Surgical intervention was performed in 12 patients (71%), and initial surgery was performed at 2 years of median age (range 2 months to 13 years). The remaining 5 patients did not undergo surgery. The reason for not performing surgery included parental refusal (patients no. 4 and 5), asymptomatic (patient no. 13), not a good candidate for surgical intervention because of long distance between main PA and IPADO (patient no. 12), and a tiny native PA that would be unlikely to grow with surgery in an older patient (patient no. 15).
The surgical approach evolved throughout the years. Initially, a direct anastomosis or anasotmosis with tube graft as one-stage surgical correction was performed in 6 patients. However, the attempt to restore blood flow failed due to obstruction of the polytetrafluoroethylene (PTFE) tube graft in 2 patients (patients no. 3 and 16). One patient (patient no. 3) underwent surgical reintervention 5 years later. Another patient (patient no. 16) did not undergo surgical reintervention and was started on calcium-channel blockers (CCBs) due to residual PAH. As a next strategy, placement of an ipsilateral modified Blalock-Taussig shunt (mBTS) or central shunt was performed before surgery using an interposition tube graft or direct anastomosis in 4 patients. Recently, we attempted stent revascularization of the PDA as a transcatheter strategy instead of surgical systemicpulmonary shunt before surgical intervention in 4 patients and were successful in 2 patients (patient no. 6 at 9 months of age and patient no. 9 at 4 years of age). The revascularization of the occluded PDA was unsuccessful in 2 patients (patient no. 1 at 6 weeks of age and patient no. 12 at 5 years of age). Patient no. 1 underwent atrial septostomy due to severe PAH and right HF (mPAP 90 mm Hg; pulmonary vascular resistance index 22.1 U 9 m 2 ), and an mBTS was placed to maintain pulmonary blood flow.
The surgical intervention included main PA to IPADO with PTFE tube graft in 5 patients, anastomosis with homograft in 4 patients, direct anastomosis of distal PA to the main PA in 2 patients, and anastomosis with bovine jugular vein graft in 1 patient. Four patients (patients no. 1, 2, 6, and 7) had catheter-balloon dilatation of the IPADO; 3 of 4 patients (patients no. 1, 2, and 6) had balloon dilatation of pulmonary arteries before surgical reanastomosis; and 1 patient (patient no. 7) had PA dilation after PA anastomosis. Table 3 lists the overall results of surgical interventions for PA rehabilitation in 12 patients. In 5 patients with available data, native PA diameter increased from 2.3 to 6.5 mm after surgical rehabilitation.
Long-Term Outcomes
On follow-up, 1 patient died due from an asthma attack (patient no. 2). She had evidence of PAH at first evaluation, and a two-stage surgical intervention was performed. The hemodynamic data by catheterization after surgery showed mild PAH (mPAP 32 mm Hg), and she was treated with bosentan and CCBs. During long term follow-up, there was no death due to surgery, hemotptysis, HAPE, HF, or PAH. Patients no. 3 and 15 are in WHO functional class III and II, respectively. The remaining 14 of 17 patients (82%) were asymptomatic in WHO functional class I (2 patients \2 years old were asymptomatic) during followup. Among 14 patients who had evidence of PAH at first evaluation, 11 underwent surgical intervention. In 5 of 11 patients (45%) who underwent surgical rehabilitation, the PAH resolved. In addition, the PAH resolved in 1 of 3 patients (33%) without surgery. Among the 3 patients who did not have PAH at first evaluation, no patient has PAH 
Discussion
This retrospective cohort study demonstrates the clinical characteristics of IPADO in pediatric patients living at modest altitude. We found that 88% of IPADO patients who live at modest altitude were symptomatic at presentation, and cyanotic spell was the initial symptom in 41% of patients. In addition, the present study demonstrated a higher incidence of PAH compared with previous reports in adults and children with IPADO (82% vs. 20% to 44%, respectively) [12, 21, 26, 29] , thus our results suggested that modest altitude increased the risk of developing PAH in patients with IPADO. The high incidence of cyanotic spells in the present study might be associated with hypoxic pulmonary vasoconstriction due to altitude as well. Living at altitude may unmask the presence of IPADO in children.
The risk at altitude likely derives from hypoxic pulmonary vasoconstriction. The level of altitude has an inverse relation to arterial oxygen saturation and a direct relationship to PAP. Increased altitude [ 3000 m is associated with important changes in arterial oxygen saturation and PAP [20] . When alveolar partial pressures of oxygen decreases \ 70 mm Hg, hypoxic pulmonary vasoconstriction causes an increase in pulmonary vascular resistance and leads to increased PAP [3] . Even in healthy subjects at high altitude, pulmonary vasoconstriction, pulmonary arterial remodeling, right-ventricular hypertrophy, erythrocytosis, and vasoconstriction are observed [15] . PAH at altitude is usually mild with mPAP of approximately 25 mm Hg in healthy subjects [20] . Anatomical abnormalities, such as IPADO with associated unilateral lung hypoplasia, may be risk factors for PAH at relatively low altitude [9, [23] [24] [25] . Previous animal studies demonstrated the hemodynamic effect of unilateral PA ligation at altitude (1600 m) and at sea level. In this study, PAH developed in neonatal calves at altitude, whereas the calves did not have PAH at sea level. The results suggested that altitude might lead to the development of PAH in patients with unilateral PA isolation [31] . Our series of patients includes the longest follow-up period: B46 years. Our study is interesting because this is the first case-cohort study to describe and find favorable long-term outcomes in IPADO patients who live at altitude.
During long-term follow-up, no patients died due to PAH in association with IPADO. Most patients with IPADO are in WHO functional class I. In most of the IPADO patients with PAH, surgical intervention during infancy could be performed for rehabilitation and growth of the pulmonary arteries because of their early presentation. The high incidence of PAH due to modest altitude might have lead to early diagnosis in our population. Early surgical or catheter intervention can preserve and may rehabilitate the pulmonary vasculature. In the recently published literature, initial repair of IPADO lead to favorable outcomes when performed during the neonatal period and infancy [2, 11, 12] . Therefore, early diagnosis of IPADO patients may prevent late mortality.
Among patients without PAH at first catheterization, no one with or without surgery has developed PAH during follow-up. In our results, it is unclear whether the patients without PAH should undergo staged surgical repair. However, in 11 PAH patients who underwent surgical rehabilitation, 6 patients had residual PAH after surgery. Although mPAP, as measured by catheterization, shows mild elevation (median 36 mm Hg), 7 of 16 patients (44%) are still receiving pulmonary vasodilator therapies. Likewise, the previous large case series showed that 30% of IPADO patients with or without surgical intervention had residual PAH during follow-up (mean 7.7 years) [30] . Our results suggested that milder forms of PAH may be observed regardless of surgery in patients with IPADO during long-term follow-up. In addition, one of our study patient with mild PAH had relapse of hemoptysis when visiting at high altitude after coil embolization of the collateral arteries. Therefore, even in IPADO patients with mild PAH after surgery, travel to high altitude may not be recommended.
Limitations
Our study was limited by small numbers because IPADO is a rare pathology and this was a retrospective cohort study from a single center. In addition, we were only able to document PA diameter before and after surgery in 5 of 12 patients. A further limitation may also be the lack of comparison data between those patients at modest altitude and at sea level. Despite these limitations, we found that modest altitude was associated with early clinical presentation, including PAH in patients with isolated IPADO. In addition, long-term outcome was favorable after surgery despite the increased risk of PAH.
Conclusion
Most IPADO patients who lived at altitude were symptomatic and have a high incidence of PAH. In IPADO patients with PAH who underwent surgical rehabilitation, 55% had resolution of PAH. Our results suggest that early surgical intervention can potentially preserve and grow the peripheral pulmonary vasculature in affected lungs of patients with IPADO. Although 44% of our patients still require medical therapy for mild residual PAH, long-term outcomes were generally favorable. In conclusion, we recommend surgical revascularization of IPADO in the setting of PAH but data are lacking in patients without PAH.
